Medical Advocates
HAART/ART
/c
ART
 
Main Page

New/Noteworthy
Children
Adolescents
Pregnant Women
Women
General Reports 
Efficacy
Drug Interactions 
Adverse Events
Viral Dynamics
Adherence



Resistance            
Quality-of-Life       
Dosing
Therapeutic Strategies
Economics
Pharmacogenetics
HIV/HCV Coinfection

Drug Index
Drug Classes
HAART/ART Failure

 

HIV Main Page Main New/Newsworthy     Home Page    

This web page is best viewed by using INTERNET EXPLORER
Last Update:  March 18, 2017
 
 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader


New and Noteworthy
 

March 2017
 

General/Miscellaneous Reports
 

     Video

 
Basics of HIV Medications by Dr. Raghuram

    Journal Papers, Abstracts, and Commentaries

 

Long-Acting Antiretrovirals: Where Are We now?
Nyaku AN, Kelly SG, Taiwo BO.
Curr HIV/AIDS Rep
. 2017 Mar 16.
Abstract

Changes in Levels of Inflammation Following Antiretroviral Treatment During Early HIV Infection in ACTG A5217.
Macatangay BJ, Yang M, Sun X,
J Acquir Immune Defic Syndr
. 2017 Feb 14.
Abstract

Barriers to Universal Prescribing of Antiretroviral Therapy by HIV Care Providers in the United States, 2013-2014.
Weiser J, Brooks JT, Skarbinski J, et al
J Acquir Immune Defic Syndr. 2016 Dec 17
Abstract

Antiretroviral Agents: Looking for the Best Possible Chemotherapeutic Options to Conquer HIV.
Farooq T, Hameed A, Rehman K, et al
Crit Rev Eukaryot Gene Expr
. 2016;26(4):363-381.
Abstract

Alveolar bone in human immunodeficiency virus infection: is it changed by long-term antiretroviral therapy?
Nittayananta W, Kanjanaprapas A, Arirachakaran P, et al
Int Dent J. 2016 Nov 18.
Abstract

Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.
Fiandra L, Capetti A, Sorrentino L, Corsi F
J Neuroimmune Pharmacol
. 2016 Nov 10.
Abstract

Marked sex differences in all-cause mortality on antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis.
Beckham SW, Beyrer C, Luckow P,
J Int AIDS Soc. 2016 Nov 8;19(1):21106
Abstract

Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
Silveira MP, Silveira CP, Guttier MC, et al.
J Clin Pharm Ther. 2016 Dec;41(6):689-694.
Abstract

Inosine Triphosphate Pyrophosphohydrolase Expression: Decreased in Leukocytes of HIV-Infected Patients Using Combination Antiretroviral Therapy.
Peltenburg NC, Leers MP, Bakker JA,  et al
J Acquir Immune Defic Syndr
. 2016 Dec 1;73(4):390-395.
Abstract

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals.
Nwogu JN, Ma Q, Babalola CP,  et al
AIDS Res Treat
. 2016;2016:2587094. Review..
Abstract

Roles and Functions of Social Networks Among Men Who Use Drugs in ART Initiation in Vietnam.
Latkin CA, Smith MK, Ha TV, et al
AIDS Behav
. 2016 Nov;20(11):2782-2789
Abstract

FULL-TEXT ARTICLE
Beyond Risk Compensation: Clusters of Antiretroviral Treatment (ART) Users in Sexual Networks Can Modify the Impact of ART on HIV Incidence.
Delva W, Helleringer S.
PLoS One
. 2016 Sep 22;11(9):e0163159.
Paper

Long-term body composition changes in antiretroviral-treated HIV-infected individuals.
Grant PM, Kitch D, McComsey GA, et al
AIDS. 2016 Sep 20.
Abstract

New Antiretroviral Treatment for HIV.
Badowski ME, Pérez SE, Biagi M, Littler JA.
Infect Dis Ther. 2016 Aug 18.
Abstract

FULL-TEXT ARTICLE
Factors associated with 10 years of continuous viral load suppression on HAART.
Bello KJ, Mesner O, O'Bryan TA,  et al
BMC Infect Dis
. 2016 Jul 22;16:351
Paper

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.
Günthard HF, Saag MS, Benson CA, et al
JAMA
. 2016 Jul 12;316(2):191-210.
Abstract

High antiretroviral coverage and viral suppression prevalence in Japan: an excellent profile for downstream HIV care spectrum
Miyazaki N, Sugiura W, Gatanaga H, et al
Jpn J Infect Dis. 2016 Jun 30.
Abstract

Outcomes of antiretroviral therapy among younger versus older adolescents and adults in an urban clinic, Zimbabwe.
Matyanga CM, Takarinda KC, Owiti P, et al  
Public Health Action
. 2016 Jun 21;6(2):97-104
Abstract

FULL-TEXT ARTICLE
Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels
Sörstedt E, Nilsson S, Blaxhult A, et al
BMC Infect Dis. 2016 Jun 21;16(1):305.
Paper

Brief Report: A High Rate of β7+ Gut-Homing Lymphocytes in HIV-Infected Immunological Nonresponders is Associated With Poor CD4 T-Cell Recovery During Suppressive HAART.
Girard A, Vergnon-Miszczycha D, Depincé-Berger AE,  et al
J Acquir Immune Defic Syndr
. 2016 Jul 1;72(3):259-65.
Abstract

FULL-TEXT ARTICLE
Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.
Ananworanich J, Chomont N, Fletcher JL, et al
J Virus Erad
. 2015;1(2):116-122.
Paper

Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy- a systematic review and meta-analysis
Farahani M, Mulinder H, Farahani A, Marlink R.
Int J STD AIDS
. 2016 Feb 10.
Abstract

Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles.
Crouzat F, Benoit AC, Kovacs C,  et al
HIV Clin Trials
. 2016 Jan;17(1):1-11.
Abstract

FULL-TEXT ARTICLE
Dynamic Perturbations of the T-Cell Receptor Repertoire in Chronic HIV Infection and following Antiretroviral Therapy.
Heather JM, Best K, Oakes T,  et al
Front Immunol
. 2016 Jan 11;6:644.
Paper

Factors associated with long-term CD4 cell recovery in HIV-infected patients on successful antiretroviral therapy.
Collazos J, Valle-Garay E, Carton JA, et al
HIV Med. 2016 Jan 11.
Abstract

Backbones versus core agents in initial ART regimens: one game, two players.
Llibre JM, Walmsley S, Gatell JM.
J Antimicrob Chemother. 2016 Jan 7.
Abstract

The impact of transient cART in early HIV infection on viral suppression and immunologic response in later treatment.
Pantazis N, Touloumi G, Meyer L, et al

AIDS
. 2015 Dec 3.
Abstract

FULL-TEXT ARTICLE
Lipid levels in HIV-positive men receiving anti-retroviral therapy are not associated with copy number variation of reverse cholesterol transport pathway genes.
Marino RB, Kingsley LA, Hussain SK, et al
BMC Res Notes. 2015 Nov 21;8(1):697.
Paper

Medication-Taking Practices of Patients on Antiretroviral HIV Therapy: Control, Power, and Intentionality.
Muessig KE, Panter AT, Mouw MS,  et al.

 AIDS Patient Care STDS
. 2015 Nov;29(11):606-616
Abstract

The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients.
Krentz HB, Gill MJ.
AIDS Patient Care STDS. 2015 Nov 6.
Abstract

FULL-TEXT ARTICLE
Single Tablet Regimen Usage and Efficacy in the Treatment of HIV Infection in Australia.
Armstrong B, Chan DJ, Stewart MJ, Fagan D, Smith D.
AIDS Res Treat. 2015;2015:570316
Paper

Antiretroviral purchasing and prescription practices in Mexico: constraints, challenges and opportunities.
Chaumont C, Bautista-Arredondo S, Calva JJ,  et al 

Salud Publica Mex
. 2015;57 Suppl 2:s171-s182.
Abstract

The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy.
Koethe JR, Grome H, Jenkins CA, et al
AIDS
. 2015 Sep 28
Abstract

Antiretroviral regimen durability and success in treatment-naďve and treatment-experienced patients by year of treatment initiation, United States, 1996-2011.
Sheth AN, Ofotokun I, Buchacz K, et al

J Acquir Immune Defic Syndr
. 2015 Aug 22.
Abstract

Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy.
Massanella M, Gianella S, Schrier R,  et al

Sci Rep
. 2015 Aug 24;5:13179. .
Abstract

The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will.
Beyrer C, Birx DL, Bekker LG,  et al
Lancet. 2015 Aug 8;386(9993):505-7
Abstract

FULL-TEXT ARTICLE
New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy).
Restelli U, Scolari F, Bonfanti P,
et al
BMC Infect Dis
. 2015 Aug 11;15(1):323
.

Paper

FULL-TEXT ARTICLE

Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada.
Patterson S, Cescon A, Samji H,  et al

BMC Infect Di
s
. 2015 Jul 17;|
Paper

Mapping chemical structure-activity information of HAART-drug cocktails over complex networks of AIDS epidemiology and socioeconomic data of U.S. counties.
Herrera-Ibatá DM, Pazos A, Orbegozo-Medina RA,  et al

Biosystems
. 2015 Apr 24.
Abstract

Effect of Universal Access to Antiretroviral Therapy on HIV/AIDS Mortality in Mexico 1990 - 2011.
Hernández-Ávila JE, Palacio-Mejía LS, Hernández-Romieu A,
J Acquir Immune Defic Syndr. 2015 Apr 13.

Abstract

Post-treatment control of HIV infection.
Conway JM, Perelson AS.
Proc Natl Acad Sci U S A. 2015 Apr 13. pii: 201419162.
.
Abstract

FULL-TEXT ARTICLE
Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?
Krastinova E, Seng R, Lechenadec J,  et al
BMC Infect Dis
. 2015 Apr 10;15(1):178.
.
Paper

FULL-TEXT ARTICLE
From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany
Schmidt D, Kollan C, Stoll M,  et al

BMC Public Health
. 2015 Mar 17;15(1):252.
Paper

FULL-TEXT ARTICLE
Persistence of Pathological Distribution of NK Cells in HIV-Infected Patients with Prolonged Use of HAART and a Sustained Immune Response
Frias M, Rivero-Juarez A, Gordon A, , et al

PLoS One
. 2015 Mar 26;10(3):e0121019.
Paper

Impact of Gender on Long-Term Treatment Outcomes of Highly Active Antiretroviral Therapy (HAART) in the TREAT Asia HIV Observational Database.
Lee MP, Zhou J, Messerschmidt L, Honda M,  et al
AIDS Patient Care STDS. 2015 Mar 16.
Abstract

Subsidized optimal ART for HIV-positive temporary residents of Australia improves virological outcomes: results from the Australian HIV Observational Database Temporary Residents Access Study.
Petoumenos K, Watson J, Whittaker B, et al

J Int AIDS Soc
. 2015 Feb 12;18(1):19392.
Paper

Antiretroviral therapy reduces neurodegeneration in HIV infection.
Bryant AK, Ellis RJ, Umlauf A,  et al
AIDS
. 2015 Jan 28;29(3):323-30
Abstract

Potential Implication of Residual Viremia in Patients on Effective ART.
Sahu GK.

AIDS Res Hum Retroviruses
. 2014 Nov 26
Abstract

FULL-TEXT ARTICLE
Residual Viremia Is Preceding Viral Blips and Persistent Low-Level Viremia in Treated HIV-1 Patients.
Hofstra LM, Mudrikova T, Stam AJ,, et al
PLoS One. 2014 Oct 29;9(10):e110749
Paper

The discovery and development of antiretroviral agents.
Lange JM, Ananworanich J.

Antivir Ther
. 2014;19(Suppl 3):5-14.
Abstract

Stimulant Use and Progression to AIDS or Mortality After The Initiation of Highly Active Anti-Retroviral Therapy.
Carrico AW, Shoptaw S, Cox C,  et al

J Acquir Immune Defic Syndr
. 2014 Sep 30
Paper

Meeting report: 27th International Conference on Antiviral Research.
Anthony Vere Hodge R.
Antiviral Res
. 2014 Sep 10.
Abstract

Treatment Outcomes Among People Living With HIV Who Are Food Insecure and Prescribed Antiretrovirals Taken With Food
Kalichman SC, Washington C, Grebler T,  et al

J Prim Care Community Health
. 2014 Sep 8
Abstract

The Demand for Antiretroviral Drugs in the Illicit Marketplace: Implications for HIV Disease Management Among Vulnerable Populations.
Tsuyuki K, Surratt HL, Levi-Minzi MA,  et al

AIDS Behav
. 2014 Aug 5.
Paper

FULL-TEXT ARTICLE
Maximizing the benefits of antiretroviral therapy for key affected populations.

Grubb IR, Beckham SW, Kazatchkine M,  et al
J Int AIDS Soc. 2014 Jul 18;17(1):19320
Paper

The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A, Rusconi S, Marzocchetti A, et al

J Med Virol
. 2014 Jul 11.
Abstract

Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure.
Rozera G, Abbate I, Giombini E,  et al
J Antimicrob Chemother. 2014 Jul 10.

Abstract

FULL-TEXT PDF ARTICLE

Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.
Estébanez M, Stella-Ascariz N, Mingorance J, et al
BMC Infect Dis. 2014 Jul 10;14(1):379
Paper

Addressing the Achilles' Heel in the HIV Care Continuum for the Success of a Test-and-Treat Strategy to Achieve an AIDS-Free Generation.
Nachega JB, Uthman OA, Del Rio C, et al
Clin Infect Dis
. 2014 Jul 1;59 Suppl 1:S21-7.

Abstract

Leveraging HIV Treatment to End AIDS, Stop New HIV Infections, and Avoid the Cost of Inaction.
Sidibé M, Zuniga JM, Montaner J.
Clin Infect Dis. 2014 Jul 1;59 Suppl 1:S3-6
Abstract

C
ROI 2014: advances in antiretroviral therapy.
Taylor BS, Shalev N, Wilkin TJ.
Top Antivir Med
. 2014 May;22(2):616-31."'

Paper

"Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.
Kang D, Song Y, Chen W, et al
Mol Biosyst
. 2014 May 20.
Abstract

FULL-TEXT ARTICLE

HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality.
Serrano-Villar S, Sainz T, Lee SA,  et al
PLoS Pathog
. 2014 May 15
Paper

Impact of risk factors for specific causes death in the first and subsequent years of ART among HIV-infected patients.
Ingle SM, May MT, Gill MJ, et al  for the Antiretroviral Therapy Cohort Collaboration.
Clin Infect Dis. 2014 Apr 24.
Abstract

The Evolution of Three Decades of Antiretroviral Therapy: Challenges, Triumphs and the Promise of the Future.
Tseng A, Seet J, Phillips EJ.

Br J Clin Pharmacol
. 2014 Apr 15.
Abstract

Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.
Yanik EL, Napravnik S, Cole SR,  et al

A
IDS
. 2014 Apr 24;28(7):979-87.
Abstract

Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: a systematic review.
Tucker JD, Bien CH, Easterbrook PJ,  et al
AIDS. 2014 Mar;28 Suppl 2:S151-60.
Abstract

FULL-TEXT ARTICLE
CD4 Counts and Viral Loads of Newly Diagnosed HIV-Infected Individuals: Implications for Treatment as Prevention.
Govender S, Otwombe K, Essien T, et al
PLoS One. 2014 Mar 4;9(3):e90754. 
Paper

FULL-TEXT ARTICLE
Association between nutritional status and the immune response in HIV + patients under HAART: protocol for a systematic review.
Sicotte M, Langlois EV, Aho J,  et al
Syst Rev. 2014 Feb 10;3(1):9.
Paper

FULL-TEXT ARTICLE
Race/ethnicity and HAART initiation in a military HIV infected cohort.
Johnson EN, Roediger MP, Landrum ML,  et al

AIDS Res Ther
. 2014 Jan 24;11(1):10
Paper

Sex Differences in HIV Outcomes in the HAART Era: A Systematic Review.
Castilho JL, Melekhin VV, Sterling TR.

AIDS Res Hum Retroviruses
. 2014 Jan 9

Abstract

New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents.
Boffito M, Jackson A, Owen A, Becker S.
Drugs. 2013 Dec 11..
Abstract

Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States.
Hughes AJ, Mattson CL, Scheer S,  et al
J Acquir Immune Defic Syndr
. 2013 Dec 8.

Abstract

FULL-TEXT ARTICLE
Modelling the Strategic Use of Antiretroviral Therapy for the Treatment and Prevention of HIV.
Ford N, Hirnschall G.
PLoS Med
. 2013 Oct;10(10):e1001535
Paper

Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?
Cohen MS, Smith MK, Muessig KE, et al
Lancet. 2013 Oct 18.|
.
Abstract

The antiretroviral drug pipeline: prospects and implications for future treatment research.
Flexner C, Saag M.
Curr Opin HIV AIDS
. 2013 Oct 4.
Abstract

Long-acting injectable antiretrovirals for HIV treatment and prevention.
Spreen WR, Margolis DA, Pottage JC Jr.
Curr Opin HIV AIDS
. 2013 Oct 4
Abstract

Single-tablet regimens in hiv: does it really make a difference?
Aldir I, Horta A, Serrado M.
Curr Med Res Opin. 2013 Sep 16.
Abstract

Separate Goals, Converging Priorities: On the Ethics of Treatment as Prevention.
Ostmann F, Saenz C.

Dev World Bioeth
. 2013 Jun 25
Abstract

A Side Door Into Care Cascade for HIV-Infected Patients?
Hallett TB, Eaton JW.
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S228-32. d.
Abstract

An Expanded Behavioral Paradigm for Prevention and Treatment of HIV-1 Infection.
Coates TJ.

J Acquir Immune Defic Syndr
. 2013 Jul;63 Suppl 2:S179-82.
Abstract

Immune interventions in HIV infection.
Carcelain G, Autran B.

Immunol Rev
. 2013 Jul;254(1):355-71.
Abstract

The Next Therapeutic Challenge in HIV: Polypharmacy.
Edelman EJ, Gordon KS, Glover J,  et al

Drugs Aging. 2013 Jun 6.
Abstract

Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance,
and the Success of HIV Treatment Programs.

Gupta RK, Wainberg MA, Brun-Vezinet F,  et a;

J Infect Dis
. 2013 Jun;207 Suppl 2:S101-6
Abstract

Low-level viremia is associated with non-B subtypes in patients infected with HIV with virological success following HAART introduction.
Saison J, Tardy JC, Scholtes C, et al
J Med Virol
. 2013 Jun;85(6):953-8.
Abstract

Aspirin attenuates platelet activation and immune activation in HIV-infected subjects on antiretroviral therapy: A Pilot Study.
O'Brien M, Montenont E, Hu L,  et al

J Acquir Immune Defic Syndr
. 2013 Feb 12..
Abstract

CD8+ T-cell Activation in HIV-1-Infected Patients Experiencing Transient Low-level Viremia During Antiretroviral Therapy.
Taiwo B, Hunt PW, Gandhi RT,  et al
J Acquir Immune Defic Syndr
. 2013 Feb 7
Abstract

Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
Hocqueloux L, Avettand-Fčnoël V, Jacquot S, et al

J Antimicrob Chemother
. 2013 Jan 20.
Abstract

The impact of antiretroviral therapy duration and intensification on isolated semen HIV-1 RNA shedding.
Osborne BJ, Sheth PM, Yi TJ, et al

J Infect Dis
. 2013 Jan 17.
Abstract

The Design of Single-Arm Clinical Trials of Combination Antiretroviral Regimens for Treatment-Naive HIV-Infected Patients.
Zheng L, Rosenkranz SL, Taiwo B, et al

AIDS Res Hum Retroviruses
. 2012 Dec 10.
Abstract

The role of intellectual property rights in treatment access: challenges and solutions.
Hoen ET, Passarelli CA.
Curr Opin HIV AIDS. 2012 Nov 29
Abstract

Fifteen million people on antiretroviral treatment by 2015: treatment as prevention.
Granich R, Williams B, Montaner J.

Curr Opin HIV AIDS
. 2012 Nov 23
Abstract

FULL-TEXT ARTICLE
Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy.
McManus H, O'Connor CC, Boyd M,
PLoS One. 2012;7(11):e48839
Paper

Optimizing HIV treatment.
Hill A.

Curr Opin HIV AIDS
. 2012 Nov 8.
Abstract

FULL-TEXT PDF ARTICLE
Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study. [Denmark]
Thorsteinsson K, Ladelund S,
Jensen-Fangel S, et al
BMC Infect Dis. 2012 Nov 12;12(1):293
Paper

Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience.
Wright S, Petoumenos K, Boyd M,  et al
HIV Med. 2012 Oct 4.
Abstract

Higher CNS Penetration-Effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
Cusini A, Vernazza PL, Yerly S,  et al

J Acquir Immune Defic Syndr
. 2012 Sep 26..
Abstract

Enhanced U.S. Army HIV diagnostic algorithm used to diagnose acute HIV infection in a deployed soldier.
Hakre S, Paris RM, Brian JE, et al

Mil Med
. 2012 May;177(5):609-13.
Abstract

The parametric g-formula to estimate the effect of highly active antiretroviral therapy
on incident AIDS or death.
Westreich D, Cole SR, Young JG,  et al
Stat Med
. 2012 Apr 11.
Abstract

FULL-TEXT ARTICLE
Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection.
Ananworanich J, Schuetz A, Vandergeeten C, et al
PLoS One. 2012;7(3):e33948
Paper

HIV-1 Antiretroviral Drug Therapy.
Arts EJ, Hazuda DJ.
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161..
Abstract

Severe immune dysregulation affects CD4+CD25hiFoxP3+ Regulatory T-cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive HAART.
Méndez-Lagares G, Del Mar Del Pozo-Balado M,  et al
J
Infect Dis
. 2012 Mar 28.
Abstract

Should We Treat Acute HIV Infection?
O'Brien M, Markowitz M.

Curr HIV/AIDS Rep
. 2012 Mar 14.
.
Abstract

Targeting strategies for human immunodeficiency virus: a combinatorial approach.
K Saxena S, Gupta A, Bhagyashree K, et al

Mini Rev Med Chem
. 2012 Mar 1;12(3):236-54..
Abstract

Bioinformatical Assistance of Selecting Anti-HIV Therapies: Where Do We Stand?
Lengauer T.
Intervirology. 2012;55(2):108-12. .
Abstract

Novel agents for the treatment of HIV-2 infection.
Peterson K, Rowland-Jones S.
Antivir Ther. 2012 Jan 25.
Abstract

Improved Estimation of the Distribution of Suppressed Plasma HIV-1 RNA in Men Receiving Effective Antiretroviral Therapy.
Schneider MF, Margolick JB, Jacobson LP,  et al

J Acquir Immune Defic Syndr
. 2012 Jan
Abstract

    Conference Reports, Abstracts, and Posters  

 
Antiretroviral therapy preserves polyfunctional HIV-1-specific CD8 T cells with stem cell-like properties
S. Vigano, J. Negron, F. Pereyra, et al

(XX International AIDS Conference)
Abstract

Characteristics of unselected HIV-positive patients over the last 15 years and treatment attitude: the Italian MASTER cohort
C. Torti, E. Raffetti, E. Focŕ, et al
(XX International AIDS Conference)
Abstract

Life expectancy (LE) of HIV-positive individuals in the HAART era (1996-2010) compared to LE in the general population: a longitudinal analysis of the COAST cohort from British Columbia (BC), Canada
O. Eyawo, K. Chan, D. Shopin. et al
(XX International AIDS Conference)
Abstract

Expanding ART delivery through a client led approach at a Ugandan NGO: pilot experiences at TASO Uganda Limited
T. Nabwire Chimulwa, A. Kasibula, A. Kateeba, et al
(XX International AIDS Conference)
Abstract

GIVAR: "Monitoring the timely access of antiretroviral drugs"
M. Castillo Castro, J.M. Campos Guevara, L. López Tocón, et al
(XX International AIDS Conference)
Abstract

Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission - The “HIV Treatment as Prevention” (TasP) experience in a Canadian setting
J. Montaner, V. Lima, P.R. Harrigan, et al
(XX International AIDS Conference)
Abstract


Efficacy Studies (also see specific Drug Studies)
       

     Journal Papers, Abstracts, and Commentaries 
 
 
Continued Slow Decay of Residual Plasma Viremia in HIV-1-infected Adults on Long Term Antiretroviral Therapy.
Riddler SA, Aga E, Bosch RJ, et al

J Infect Dis
. 2015 Sep 2. pii: jiv4
Abstract

Safety and Effectiveness of Highly Active Antiretroviral Therapy in Treatment-Naďve HIV Patients: Preliminary Findings of a Cohort Event Monitoring Study in Belarus.
Setkina S, Dotsenko M, Bondar S, et al 
Drug Saf. 2015 Mar 26.
Abstract

Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
Crawford K, Wakabi S, Magala F, et al

HIV Med
. 2014 Aug 15.
Abstract

Immunological Recovery After 24 Weeks of Antiretroviral Therapy in Patients With X4 Virus During Primary HIV Infection
Nozza S, Pignataro AR, Galli L,  et al

J Acquir Immune Defic Synd
r
. 2014 Jan 1;65(1):e27-9..
Abstract

Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs.
Wilson EM, Sereti I.
Immunol Rev. 2013 Jul;254(1):343-54.
Abstract

Effect of antiretroviral therapy on inflammatory markers of endothelial dysfunction in HIV treatment-Naďve infected patients.
Mata-Marín JA, Méndez-Cruz R, Arroyo-Anduiza CI,  et al

J Med Virol
. 2013 Aug;85(8):1321-6..
Abstract

Improvements in virological control among women conceiving on cART in Western Europe.
Bailey H, Townsend CL, Cortina-Borja M,  et al

AIDS. 2013 Jun 3
Abstract

Differential patterns of CD4 recovery following effective treatment with HAART.
Wong N, Lee M, Lee P, Lee S.

J Int AIDS Soc
. 2012 Nov 11;15(6):18193..
Abstract

Increasingly Successful Highly Active Antiretroviral Therapy Delays the Emergence of New HLA Class I-Associated Escape Mutations in HIV-1.
Knapp DJ, Brumme ZL, Huang SY,  et al

Clin Infect Dis
. 2012 Mar 28.
Abstract

Effects of highly active antiretroviral therapy on cognitive functions in severely immune-compromised HIV-seropositive patients.
Obiabo YO, Ogunrin OA, Ogun AS.

J Neurol Sci
. 2011 Oct 11.
Abstract

FULL-TEXT ARTICLE
Does HAART efficacy translate to effectiveness? Evidence for a trial effect.
Menezes P, Miller WC, Wohl DA, et al
PLoS One. 2011;6(7):e21824.
Paper

Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.
Cescon A, Cooper C, Chan K, et al

HIV Med
.
2010 Nov 8
Abstract

 


Quality of Life
 

      Journal Papers, Abstracts, and Commentaries
 
 
A systematic review of cohort studies of the quality of life in HIV/AIDS patients after antiretroviral therapy.
Jin Y, Liu Z, Wang X, Liu H et al,

Int J STD AIDS
. 2014 Mar

Abstract

Dosing
       

     Journal Papers, Abstracts, and Commentaries
 
 
Treatment of HIV infection with once-daily regimens.
Permpalung N, Putcharoen O, Avihingsanon A, Ruxrungtham K.

Expert Opin Pharmacothe
r
. 2012 Nov;13(16):2301-17|
Abstract

Pharmacogenetics (also see pharmacogenetic data for specific ARVs)
       

     Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT ARTICLE
Pharmacogenetics as a tool to tailor antiretroviral therapy: A review.
Aceti A, Gianserra L, Lambiase L,  et al

World J Virol
. 2015 Aug 12;4(3):198-208.
Paper

Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.
Haas DW, Tarr PE.
Curr Opin HIV AIDS. 2015 Jan
Abstract

Pharmacogenetics of antiretrovirals.
Tozzi V.
Antiviral Res. 2009 Sep 7
Abstract

HIV Pharmacogenetics in Clinical Practice: Recent Achievements and Future Challenges.
Tozzi V, Libertone R, Liuzzi G.,et al

Curr HIV Res
. 2008 Nov;6(6):544-54.

Abstract

Selecting anti-HIV therapies based on a variety of genomic and clinical factors.
Rosen-Zvi M, Altmann A, Prosperi M, et al
Bioinformatics. 2008 Jul 1;24(13):i399-406
Abstract
 
Pharmacogenomics of antiretrovirals.
Roca B.
Recent Patents Anti-Infect Drug Disc. 2008 Jun;3(2):132-5
Abstract
 
Hypersensitivity syndrome--the role of pharmacogenetics for prediction of efficacy and safety of antiretroviral therapy in patients with HIV/AIDS
Cholewińska G.
Przegl Epidemiol. 2008;62(1):149-54.
Abstract
 
Pharmacogenetics and the potential for the individualization of antiretroviral therapy.
Phillips EJ, Mallal SA.
Curr Opin Infect Dis. 2008 Feb;21(1):16-24.
Abstract
 
 


HIV Main Page Main New/Newsworthy     Home Page    

HAART/ART/cART